Chemotherapy Related Topics 
Pharmacy Times
SEPTEMBER 2, 2022
DNA and RNA sequencing could provide insight about resistance to chemotherapy in patients suffering from triple-negative breast cancer.
Pharmafile
MARCH 3, 2023
Scientists from the Institute of Cancer Research London, Imperial College London and the Netherlands Cancer Institute have researched a gene test which can select which advanced bowel cancer patients will respond the best to chemotherapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmafile
NOVEMBER 28, 2022
South Korean biotech firm Hyundai Bioscience’s innovative chemotherapy drug may be able to complete cancer treatments in two doses. The new anticancer drug, Polytaxel, is set to enter a clinical trial on pancreatic cancer being held in Australia. read more. Research and Development
Pharmacy Times
JULY 19, 2022
Treatment's approval marks exciting new development for patients with ES-SCLC to prevent CIM.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.
Pharma Phorum
FEBRUARY 10, 2021
The PHERGain II study’s goal is to find an effective therapeutic strategy that can reduce the use of chemotherapy and improve the quality of life of patients without compromising the clinical effectiveness of their treatment.
Pharmaceutical Technology
MARCH 30, 2023
The European Commission (EC) has granted approval for Regeneron Pharmaceuticals’ Libtayo (cemiplimab), along with platinum-based chemotherapy, as the first-line treatment for PD-L1 expression positive advanced non-small cell lung cancer (NSCLC) in adult patients.
Fierce Pharma
SEPTEMBER 21, 2022
Fennec finally pushes drug to prevent chemotherapy-induced hearing loss across the FDA finish line. esagonowsky. Wed, 09/21/2022 - 09:58
Pharmafile
FEBRUARY 1, 2023
It appears that adding veliparib to chemotherapy can extend progression-free survival (PFS) in patients suffering from triple negative breast cancer (TNBC) with a ‘BRCA-like’ phenotype.
Pharma Mirror
MARCH 8, 2021
The post The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy appeared first on Pharma Mirror Magazine.
Pharmacy Times
NOVEMBER 9, 2022
Efficacy results comparing the cemiplimab-rwlc combination to chemotherapy alone showed a 22-month median overall survival versus 13 months.
Pharmaceutical Technology
NOVEMBER 9, 2022
The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals ’ PD-1 inhibitor Libtayo (cemiplimab-rwlc) and chemotherapy combination as the first-line treatment for advanced non-small cell lung cancer (NSCLC).
Pharma Phorum
NOVEMBER 9, 2021
Lung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable non-small cell lung cancer (NSCLC). The post Opdivo and chemotherapy combo increases survival in lung cancer patients appeared first on.
Pharmacy Times
NOVEMBER 11, 2022
Tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy approved for the treatment of adults with metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.
Pharmacy Times
SEPTEMBER 6, 2022
Results from the TOPAZ-1 phase 3 trial showed that the combination reduced risk of death by 20% versus chemotherapy alone.
Pharmacy Times
OCTOBER 6, 2022
Results from the largest head-to-head trial of programmed death receptor-1 inhibitors suggest that dostarlimab and chemotherapy could be an effective treatment option for patients with metastatic non-squamous non-small cell lung cancer.
Pharmaceutical Technology
MARCH 14, 2023
Platinum-based cancer drug compositions is a key innovation area in chemotherapy Platinum-based drugs are chemotherapeutic agents used for the treatment of cancer.
Pharmaceutical Technology
MARCH 14, 2023
Purine derivatives-based cancer drug compositions is a key innovation area in chemotherapy Purine is an important heterocyclic nucleus in the chemical architecture of many bioactive compounds.
Pharmacy Times
MARCH 21, 2023
For the management of ovarian cancer, it has been observed in both cellular and animal models that curcumin suppresses cell proliferation and promotes apoptosis.
Pharmacy Times
NOVEMBER 28, 2022
The trial data demonstrated that pembrolizumab in combination with chemotherapy also had statistically significant and clinically meaningful improvements in PFS and ORR as well.
Pharmacy Times
DECEMBER 8, 2022
DESTINY-Breast02 clinical trial results show trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in progression-free and overall survival.
Pharma Phorum
JANUARY 3, 2023
Over recent years, there has been a growing consensus that using chemotherapy and aggressive treatments towards the end-of-life should be avoided, where possible, due to the lower quality of life reported.
Pharmacy Times
SEPTEMBER 20, 2022
Phase 3 TOPAZ-1 trial of AstraZeneca’s durvalumab demonstrates an improved overall survival benefit.
Pharmacy Times
JANUARY 27, 2023
Chronochemotherapy aims to time drug delivery when the body is the least vulnerable to harmful effects, while the cancer cells are the most vulnerable.
Pharmacy Times
JANUARY 26, 2023
Specific data and results for pembrolizumab in patients with advanced or unresectable biliary tract cancer will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.
Pharmacy Times
AUGUST 17, 2022
Gilead Sciences Inc submitted a supplemental Biologics License Application to the FDA for sacituzumab govitecan-hziy (Trodelvy) following promising trial results.
Pharmacy Times
OCTOBER 5, 2022
Currently available agents may reduce the need for stem cell transplantation in patients with acute lymphocytic leukemia.
Pharma Phorum
SEPTEMBER 13, 2022
While they may not have known it at the time, through their work Ehrlich and Metschnikow formed the cornerstone of modern immunology, including chemoreceptor and chemotherapy concepts that revolutionised blood cancer treatment over the following century.
Pharma Times
FEBRUARY 19, 2021
AVA6000 is pro-drug form of the chemotherapy doxorubicin, modified using Avacta's pre|CISION chemistry
Pharma Times
JANUARY 7, 2022
With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer in the UK
Pharma Phorum
NOVEMBER 5, 2020
Robert decided to enrol on a clinical trial of chemotherapy plus high dose vitamin D at the University of Pennsylvania. Oncology Patients Views & Analysis Views and analysis cancer chemotherapy patient voices
Pharma Mirror
JULY 23, 2020
The two-year research partnership will focus on improving the benefit/risk ratio of chemotherapy by decreasing gut inflammation caused by chemotherapy to potentially improve response rates through modulation. Pharmaceutical News Chemotherapy Collaboration DuPont Rutgers University
Pharma Phorum
AUGUST 3, 2022
Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cancer (SCLC). News Oncology R&D chemotherapy Ipsen Onivyde Servier small cell lung cancer
Pharmacy Times
DECEMBER 19, 2022
Specific immune checkpoint inhibitors added to frontline chemotherapy have transformed modern clinical practice.
Pharma Times
OCTOBER 23, 2020
Keytruda backed for monotherapy treatment but combination therapy rejected
Pharma Phorum
DECEMBER 1, 2021
BeyondSpring’s hopes of an early Christmas gift from the FDA were dashed today after the regulator said it was unable to approve the company’s lead drug plinabulin as a treatment for low white blood cell counts caused by cancer chemotherapy.
Pharmafile
MARCH 28, 2023
GSK has announced promising results from part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) alongside standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab, compared to chemotherapy and a placebo, in adult patients with primary advanced or recurrent endometrial cancer.
Pharmacy Times
DECEMBER 7, 2022
When used with chemotherapy, pembrolizumab provides a synergistic response to increase survival rates.
Pharmacy Times
AUGUST 5, 2022
The FDA approved a new drug that treats unresectable and metastatic HER2-low breast cancer, giving patients with this new subtype a treatment beyond chemotherapy.
Pharmacy Times
MARCH 15, 2023
Adding durvalumab to neoadjuvant chemotherapy to treat resectable early-stage non–small cell lung cancer did not increase complications and adverse events or comprise patients’ ability to undergo surgery versus chemotherapy alone.
Pharmacy Times
OCTOBER 26, 2022
Research suggests that positron emission tomography scans are effective at detecting early and late Hodgkin’s lymphoma, and the results could help manage and reduce toxicity from current chemotherapies.
Pharmacy Times
NOVEMBER 3, 2022
It may be worth considering the pathophysiology and vascular complications of chemotherapy, especially among patients who are already hypertensive.
Pharma Times
AUGUST 18, 2021
Phase III trial showed significant survival benefit over chemotherapy alone
Expert insights. Personalized for you.
156 
Let's personalize your content